

Resource Summary Report

Generated by T1D on Sep 5, 2026

Tecan: SPARK Multimode Microplate Reader

RRID:SCR_021897

Type: Tool

Proper Citation

Tecan: SPARK Multimode Microplate Reader (RRID:SCR_021897)

Resource Information

URL: <https://lifesciences.tecan.com/multimode-plate-reader>

Proper Citation: Tecan: SPARK Multimode Microplate Reader (RRID:SCR_021897)

Description: Multimode microplate reader as fully flexible detection platform with automation. Has four configurations to select from and then add or remove options. Optimised for genomics and proteomics, microbiology, cell based assays, and drug discovery areas. Performs measurements of fluorescent cell based assays. Has integrated, bright field cell imaging module. Enables label free cell counting, size distribution determination and trypan blue based cell viability analysis.

Synonyms: plate reader, Tecan Trading AG, instrument, SPARK, SPARK plate reader, SPARK system, USEDit, acquipment, Spark, Spark multimode reader, SPARK Multimode Microplate Reader

Resource Type: instrument resource

Availability: Restricted

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_021897.pdf

Resource Name: Tecan: SPARK Multimode Microplate Reader

Resource ID: SCR_021897

Record Creation Time: 20220421T050137+0000

Record Last Update: 20260903T235730+0000

Ratings and Alerts

No rating or validation information has been found for Tecan: SPARK Multimode Microplate Reader.

No alerts have been found for Tecan: SPARK Multimode Microplate Reader.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Kamgar M, et al. (2026) Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma. Cancer research, 86(8), 2042.

Balzasch BM, et al. (2026) Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids. Oncoimmunology, 15(1), 2633012.

Maeda M, et al. (2026) CRISPR screen of human pancreatic cancer xenografts identifies a KLF5 proliferation vulnerability through epigenetic modifiers NCAPD2 and MTHFD1. Molecular cancer, 25(1).

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. EMBO molecular medicine, 18(6), 2322.

Ma J, et al. (2026) Alcohol-Induced Metabolic Stress Sensed by m6A-Modified ChREBP Drives Immune Evasion in Esophageal Carcinogenesis. Cancer research.

Kolodziejczak AS, et al. (2026) Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma. iScience, 29(2), 114564.

Goel T, et al. (2026) Disruption of chrna5 blunts aversion and adaptive transcriptomic responses to nicotine and alcohol. iScience, 29(2), 114735.

Peirano E, et al. (2026) Trio analysis in dystonia identifies de novo KLC1 variants in a kinesinopathy with distinct motor and neurodevelopmental features. EBioMedicine, 129, 106358.

Wang P, et al. (2025) Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. Cancer research communications, 5(5), 792.

Xiong EH, et al. (2025) Protocol to identify genes important for Candida albicans fitness in diverse environmental conditions using pooled bar-seq screening approach. STAR protocols, 6(1), 103645.

Yamauchi I, et al. (2025) Transcriptomic landscape of hyperthyroidism in mice overexpressing thyroid-Stimulating hormone. *iScience*, 28(1), 111565.

Markusson S, et al. (2025) Nanobodies against the myelin enzyme CNPase as tools for structural and functional studies. *Journal of neurochemistry*, 169(1), e16274.

Wischnewski V, et al. (2025) The local microenvironment suppresses the synergy between irradiation and anti-PD1 therapy in breast-to-brain metastasis. *Cell reports*, 44(3), 115427.

Giuntini F, et al. (2025) MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. *Cell reports*, 44(12), 116604.

Goto Y, et al. (2024) A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. *Cancer research communications*, 4(7), 1850.

Baumann V, et al. (2024) Faa1 membrane binding drives positive feedback in autophagosome biogenesis via fatty acid activation. *The Journal of cell biology*, 223(7).

Springer AD, et al. (2024) Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma. *Cancer research communications*, 4(10), 2660.

Panarello S, et al. (2024) Photoswitchable positive allosteric modulators of metabotropic glutamate receptor 4 to improve selectivity. *iScience*, 27(6), 110123.

Hoh KL, et al. (2024) Protocol to compare relative protein-liposome binding affinity using a fluorescence microscopy-based approach. *STAR protocols*, 6(1), 103507.

Sulsenti R, et al. (2024) Intracellular Osteopontin Promotes the Release of TNF?? by Mast Cells to Restrain Neuroendocrine Prostate Cancer. *Cancer immunology research*, 12(9), 1147.